Metabolic abnormalities found in epileptogenic tissue provide considerable evidence of brain hypometabolism, while major risk factors for acquired epilepsy all share brain hypometabolism as one common outcome, suggesting that a breakdown of brain energy homeostasis may actually precede epileptogenesis. However, a causal link between deficient brain energy metabolism and epilepsy initiation has not been yet established. To address this issue we developed an in vivo model of chronic energy hypometabolism by daily intracerebroventricular (i.c.v.) injection of the nonmetabolizable glucose analog 2-deoxy-D-glucose (2-DG) and also investigated acute effects of 2-DG on the cellular level. In hippocampal slices, acute glycolysis inhibition by 2-DG (by about 35%) led to contrasting effects on the network: a downregulation of excitatory synaptic transmission together with a depolarization of neuronal resting potential and a decreased drive of inhibitory transmission. Therefore, the potential acute effect of 2-DG on network excitability depends on the balance between these opposing preand postsynaptic changes. In vivo, we found that chronic 2-DG i.c.v. application (estimated transient inhibition of brain glycolysis under 14%) for a period of 4 weeks induced epileptiform activity in initially healthy male rats. Our results suggest that chronic inhibition of brain energy metabolism, characteristics of the well-established risk factors of acquired epilepsy, and specifically a reduction in glucose utilization (typically observed in epileptic patients) can initiate epileptogenesis.
INTRODUCTION
The involvement of energy metabolism disruption in epileptogenesis is widely accepted (Pan et al., 2008) , although precise mechanistic links and causality between the process of energy production and neuronal hyperactivity are still under investigation. Importantly, hypometabolism, manifested in humans as reduced brain glucose consumption (Goffin et al., 2008) , is a principal factor in acquired epilepsy (Pan et al., 2008; Kudin et al., 2009) . Nevertheless, one popular research trend proposes that inhibition of energy metabolism may have a profitable antiepileptic effect. The idea is largely based on the effects of a low-carbohydrate, high-fat ketogenic diet (KD), the only clinically accepted metabolic intervention for treating intractable pediatric epilepsy (Kossoff and 
SIGNIFICANCE
The precise mechanisms of acquired epilepsy development are not yet fully understood. A number of risk factors have been identified, such as traumatic brain injury, infection, and stroke-all sharing brain hypometabolism as one common outcome. Meanwhile, a shortage in glucose consumption is also observed in epilepsy patients. We found that inducing a chronic inhibition in glucose consumption in the brains of healthy rats results in epilepsy. Our results suggest that brain hypometabolism is not just a side effect of a disease but is instead a primary initiating factor in acquired epilepsy. Hartman, 2012; Rho, 2015) ; one presumptive consequence of KD's partial substitution of glucose with ketone bodies as mitochondrial fuel is the inhibition of glycolysis, and therefore many studies attempting to replicate core therapeutic benefits of KD have focused specifically on the potential antiepileptic role of glycolysis inhibition. It was reported, for example, that administration of the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) (GarrigaCanut et al., 2006; Stafstrom et al., 2009) or lactate dehydrogenase inhibitors (Sada et al., 2015) produced an acute antiepileptic effect. However, whether chronic glycolysis arrest would replicate these results has not been elucidated. All the while, metabolic abnormalities found in epileptogenic tissue (Kudin et al., 2009; Reid et al., 2014) provide considerable evidence of brain hypometabolism and suggest that a breakdown of brain energy homeostasis may actually precede epileptogenesis (Jupp et al., 2012; Lee et al., 2012) . Therefore, there is a potential danger in attempts to inhibit brain glycolysis as this may only further aggravate the existing metabolic crisis. The important question that has to be addressed is the causality of brain hypometabolism and epileptogenesis-in other words, whether energy crisis is itself an initiating and driving factor for epileptogenesis, or it whether is simply a consequence of hyperactivity. To address this issue we developed an in vivo model of chronic energy hypometabolism by daily intracerebroventricular (i.c.v.) injection of 2-DG. We found that chronic 2-DG application induces epileptiform activity in initially healthy rats, suggesting that inhibition of brain glycolysis is an initiating factor for epilepsy and highlighting the risk of such treatment strategies.
MATERIALS AND METHODS

Animals
All animal protocols were approved by the INSERM Ethics Committee for Animal Experimentation (#30-03102012), Norra Stockholms Djurf€ ors€ oksetiska N€ amnd (N45/ 13), and Russian State Standard (P BCO 10993-2-2009). All animal experiments have been conducted and reported in compliance with the ARRIVE guidelines. Nine OF1 male mice were used for acute experiments on brain slices. Chronic experiments were carried out on 37 adult Sprague-Dawley male rats. The weight of animals was approximately 30 to 40 g for mice and 220 g for rats at the beginning of the experiments. Animals were housed in individual cages with enrichment: and under 12:12-hr light/dark cycles, with food and water available ad libitum. All experiments were performed between 10:00 and 15:00. Animal weight was monitored throughout the trial.
Slice Experiments
Brain slice preparation. The brain was rapidly removed from the skull and placed in the ice-cold ACSF. The ACSF solution consisted of (in millimolar) NaCl 126, KCl 3.50, NaH 2 PO 4 1.25, NaHCO 3 25, CaCl 2 2.00, MgCl 2 1.30, and dextrose 5, pH 7.4. ACSF was aerated with 95% O 2 /5% CO 2 gas mixture. Sagittal slices (350 mm) were cut using a tissue slicer (Leica VT 1200s, Leica Microsystem, Germany). During cutting, slices were submerged in an ice-cold ( < 6 8C) solution consisting of (in millimolar) K-gluconate 140, HEPES 10, Nagluconate 15, EGTA 0.2, NaCl 4, pH adjusted to 7.2 with KOH. Slices were immediately transferred to a multisection, dual-side perfusion holding chamber with constantly circulating ACSF and allowed to recover for 2 hr at room temperature (22 8C-24 8C).
Single-cell electrophysiology (E m and E GABA measurements). For cell-attached single-channel recordings: NMDA receptor currents reverse close to 0 mV; therefore, in cell-attached recordings, measurement of the reversal potential for NMDA currents gives the value for the resting membrane potential (E m ). Meanwhile, measurement of the reversal potential of the GABA receptor currents provides the driving force for the GABA-induced currents. Single-channel recordings were performed using a pipette solution containing (in millimolar) (1) for recordings of single GABA channels: NaCl 140, KCl 2.5, CaCl 2 2, MgCl 2 1, HEPES 10, GABA 0.01, pH adjusted to 7.3 with NaOH; and (2) for recordings of single NMDA channels: NaCl 140, KCl 2.5, CaCl 2 2, HEPES 10, NMDA 0.01, glycine 0.01, pH adjusted to 7.3 with NaOH. In case of acute (naive animals) 2-DG application, slices were incubated for at least 1 hr in a vapor-interface holding chamber in ACSF containing 5 mM glucose and 7 mM 2-DG prior to being transferred to a submerged recording chamber perfused with the same solution. The 7 mM 2-DG in the presence of 5 mM glucose should inhibit glucose transport into the cells by about 35% (Bachelard 1971; Meldrum and Horton 1973) ; control slices were held in 5 mM-glucose ACSF throughout. E m and reversal potentials of GABA-mediated currents (E GABA ) were then measured in gramicidin-patch recordings with local GABA pulsed application, as described previously (Rheims et al., 2009; Zilberter et al., 2013) .
Synaptic stimulation and field potential recordings. Schaffer collateral/commissure or perforant path was stimulated using the DS2A isolated stimulator (Digitimer Ltd.) with a bipolar metal electrode. Stimulus current was adjusted using single pulses (40-170 mA, 200 msec, 0.15 Hz) to induce a local field potential (LFP) of about 50% maximal amplitude. LFPs were recorded using glass microelectrodes filled with ACSF, placed in stratum pyramidale or granular cell layer and connected to the ISO DAM-8A amplifier (WPI, FL). Following control recordings, LFPs were recorded 40 min after the addition of 2-DG. Synaptic stimulation consisted of a stimulus train (200-msec pulses) at 10 Hz for 10 sec. For lowglucose response decay experiments, slices were perfused with 10 mM glucose ACSF, and test pulses were delivered at 10-sec intervals with a constant current stimulus (0.2 msec, up to 0.3 mA), evoking LFP responses equivalent to 50% of the maximum response. After recording a stable baseline for at least 10 min, slices were subjected to glucose deprivation, induced by modified 0.1 mM glucose ACSF for at least 60 min. The integral of the evoked LFP response was measured and normalized to baseline values.
NAD(P)H fluorescence imaging. NADPH and
NADH have similar optical properties; therefore, it is expected that NADPH may contribute to the total autofluorescence signal. Changes in NAD(P)H fluorescence in hippocampal slices were monitored using a 290-to 370-nm excitation filter and a 420-nm long-pass filter for the emission (Omega Optical, Brattleboro, VT). The light source was the Intensiligh C-HGFI illuminator (Nikon Instruments Europe B.V.) equipped with a mercury arc lamp. Slices were epi-illuminated and imaged through a Nikon upright microscope (FN1, Eclipse) with 43/ 0.10 Nikon Plan objective. Images were acquired using a linear, cooled 12-bit CCD camera (Sensicam, PCO AG, Germany) with 640 3 480 digital spatial resolution. Because of a low level of fluorescence emission, NAD(P)H or FAD images were acquired every 600 to 800 msec as 8 3 8 binned images (effective spatial resolution of 80 3 60 pixels). The exposure time was adjusted to obtain a baseline fluorescence intensity between 2,000 and 3,000 optical intensity levels (50% of dynamic range). Fluorescence intensity changes in stratum radiatum near the sites of LFP and pO 2 recordings were measured in three to five regions of interest using ImageJ software (NIH). Data were expressed as percentage of change in fluorescence over a baseline [(DF/F) Á 100]. As the fluorescence intensity varies between experiments, the oxidation to reduction (dip-overshoot) ratios were used to average and ascertain the energy metabolism effects of 2-DG.
Oxygen, glucose, and lactate measurements. A Clark-style oxygen microelectrode (tip diameter 10 mm; Unisense Ltd.) was used to measure slice tissue pO 2 . Tissue glucose and lactate concentrations were measured with enzymatic microelectrodes (tip diameter 25 mm; Sarissa Biomedical, Coventry, UK). Electrodes were connected to a picoammeter (Unisense Ltd.). Calibration was performed after the first polarization and was repeated after each experiment. In analysis, oxygen consumption was estimated as an integral of pO 2 transients below the baseline.
In vivo Experiments
Chronic brain glucose hypometabolism in rats. The study was carried out on two groups of rats: control (n 5 16) and rats with chronic brain glucose hypometabolism (n 5 21) created by daily i.c.v. administration of 2-DG for 1 month. 2-DG is a synthetic glucose analog that competes with glucose for carrier-mediated transport into the mammalian brain. It is also competitively phosphorylated to 2-deoxyglucose 6-phosphate, which cannot be converted to fructose-6-phosphate by phosphoglucose isomerase, thereby inhibiting glycolysis. Direct injections of 2-DG into the brain produced localized cellular glucopenia in the absence of systemic hypoglycemia (Borg et al., 1999) and excluded any potential negative effects of glycolysis inhibition in other organs. We injected a 2.5-ll bolus of 2-DG solution (20 mM) intraventricularly (8.2 micrograms). Taking the total volume of cerebrospinal fluid of about 90 ll (Pardridge, 2011) , and assuming fast diffusion through the fluid (facilitated in part by cilia of ependymal cells), 2-DG distributed evenly at a final concentration of 0.56 mM. Since 2-DG transported to cells through extracellular fluid (ECF) with a volume of only 1 ll in rat brain (Pardridge, 2011) , one can assume that the final ECF 2-DG concentration will equalize at 0.56 mM as well. The ECF glucose concentration in adult rat hippocampus is about 1.3 mM (Zilberter et al., 2010) . 2-DG and glucose share the same membrane transport system, but the limiting factor for glycolytic rate is hexokinase activity. The relative glycolysis rate can be calculated by the following formula:
U 5 U max ½Glu=ð½Glu1K m ð11½2DG=K i Þ with Michaelis constant for glucose phosphorylation (K m ) 5 0.07 mM, and inhibition constant for 2-DG, (K i ) 5 0.3 mM (Bertoni, 1981) . Thus, the injection of 2.5 ll of 20 mM 2-DG solution results in a calculated 14% inhibition of glycolysis. Animals with vehicle 0.9% NaCl i.c.v. administration (2.5 ml) were used as controls.
After 4 weeks of i.c.v. drug administration, one group of rats was used for LFP recordings with following NMR analyses, and the other group was used for pentylenetetrazol (PTZ) tests and ex vivo experiments. For ex vivo experiments, the brain was extracted approximately 12 hr after the last 2-DG/vehicle injection.
Stereotaxic surgery. Rats were operated on under i.p. anesthesia with Zoletil (24 mg/kg, i.m.) and Xylazine (12 mg/kg, i.m.). For i.c.v. drug administration by Hamilton syringe, the guide cannula was dipped over the lateral cerebral ventricle (AP 5 20.8; L 5 1.0; H 5 3.0). For the recording of hippocampal LFPs, insulated 100-mm thin nichrome electrodes were implanted into the dentate gyrus region of the anterior hippocampus on the ipsilateral side (AP 5 23.6; L 5 2.0; H 5 3.6). The reference electrode was screwed into the occipital bone. The experiments started no earlier than a week after surgery. For animals used for ex vivo (n 5 8) experiments and PTZ test (n 5 12), only the guide cannula was implanted.
LFP recordings. LFPs of freely moving rats were amplified (Grass Instrument), filtered (high-pass filter 0.1 Hz, digitized at 5 kHz), and stored using DataPack2k software (RUN Technologies). Experimental protocol: LFPs were recorded for a control period of several days followed by a period of daily vehicle or 2-DG administration. Each rat was recorded every 3 days. LFPs were recorded throughout the entire period of the drug administration.
All recordings were performed in awake, freely moving animals, which were held in their own cages (to minimize stress from state changes) placed in a Faraday cage. Each recording session was preceded by a 15-min adaptation period of animals to the experimental conditions. Recordings were performed between 10:00 and 15:00 hr. The average duration of an experiment was about 2.5 hr. Animals were monitored and controlled to keep them awake during recordings. Further analysis revealed no significant differences in LFPs recorded under different behavioral states (such as lying or strolling). This lack of variability is likely due to environmental factors such as the complete absence of external stimuli (familiar small enclosure, loneliness, uniform background, lack of food/drink, inactive time of day). Therefore, LFPs recorded in various behavioral states were pooled in the analysis. Afterwards, the brains were snap frozen in liquid nitrogen and subsequently used for NMR analysis.
LFP analysis. To evaluate the number and duration of high-amplitude spikes, the records' standard deviation (SD) was calculated from sufficiently long periods of basal activity ( > 3 min) emanating from a region remote from the stimulation. The program scanned the trace and selected all events above the threshold level equal to 5 SD within the duration range of 50 to 990 msec.
To evaluate the LFP activity that exceeded the basal level (accumulated activity), we used the following procedure: the LFP recording was normalized to SD, and the threshold was set as 3 SD. The program scanned the trace and selected all events above the threshold level. All negative events were inverted. Thereafter, the program calculated the sum of event peaks within each consecutive period of time. Since LFP recordings were normalized, the accumulated activity could be averaged within each animal group.
To compare the high-frequency burst (HFB) events, the algorithm scanned LFP recordings filtered in the range of 60 to 600 Hz and selected all events exceeding a threshold of 7 RMS (root mean square of baseline). From these events, those exceeding the 7-RMS threshold in traces filtered at 100 to 250 Hz and 250 to 600 Hz were further analyzed. Only events consisting of more than five oscillations were considered for analysis. A similar procedure has been used previously (Staba et al., 2002) . For detecting and evaluating spontaneous seizures, we used automated computer analysis of LFP recordings with the following selection limits: seizure threshold 7 RMS of baseline; number of oscillations in scanning window (5 sec) exceeding the threshold no less than 10; minimal seizure duration 10 sec.
PTZ sensitivity test. Separate groups of vehicletreated (n 5 6) and 2-DG-treated (n 5 6) animals were created to investigate sensitivity to subconvulsive doses of PTZ (35 mg/ kg). Initially, PTZ was injected before surgery and chronic procedures to test control reactions. After 4 weeks of i.c.v. 2-DG (or vehicle for control) treatment, a second injection of subconvulsive PTZ was made. A PTZ test was performed 24 hr after the last 2-DG/vehicle injection. Seizure severity evaluation was based on the behavioral patterns in terms of W. Fischer and H. Kittner's study (1998) : no seizure (stage 0); weak nodding (stage 0.5); ear, face, and eyelid twitching (stage 1); mild forelimb clonus (stage 1.5); myoclonic body jerks, clonic convulsions of forelimb (no rearing) (stage 2); partial rearing and rapid clonic seizures of forelimb (stage 2.5); powerful bilateral forelimb clonus with complete rearing ( ! 10 sec) (stage 3); rearing and falling with intense bilateral forelimb clonus (stage 3.5); generalized clonic seizures with rearing-falling down episodes, or jumping (stage 4); generalized clonic-tonic seizures with failure of righting reflex (stage 4.5); generalized clonic-tonic seizures and status epilepticus ( ! 2 min) (stage 5).
Brain metabolite measurements by NMR.
Rat whole heads were frozen in liquid nitrogen just after decapitation (Ferrendelli et al., 1972; Du et al., 2015) . Although this technique is known to preserve some but not all labile metabolites, detected changes can still be reliably associated with the developed pathological state, as the labile metabolite levels following decapitation are dependent on autolysis but not on neuronal excitability (Pont en et al., 1973) .
After complete freezing, they were held at 215 8C for 1 hr, and then the brain was extracted, fragmented, and stored in liquid nitrogen. Equal weights of chloroform (CDCl 3 ) and then 700 ll of D 2 O were added to frozen samples, homogenized with a glass ball in a shaker for 30 sec, and centrifuged at 15,000g for 5 min. Sixty microliters of 4 lM solution of 3 trimethylsilyl [2,2,3,3-2H 4 ] propionate (TSP) in D 2 O was added to 540 ll of the supernatant, stirred, and placed in an NMR tube. 1D and 2D COSY spectra were recorded on an AVANCE III 600 NMR spectrometer (Bruker) operated at 600 MHz for protons using standard pulse sequences, in 5 mm tubes at 298 8K. Water suppression was achieved by presaturation with the ZGPR 1D pulse sequence. The number of acquisitions was 128 scans with 10-sec intervals, sufficient for proton relaxation in all observed metabolites. Free induction decay was registered for 96 K points over 3.41 sec, with the spectral width of 24 ppm and the 90 8 pulse of 11 lsec and Fourier transformed after zero filling to 128 K points. The calibration of chemical shifts was performed for the TSP signal at 0.00 ppm, which served as the internal reference. The 2D COSY sequence COSYGPPRQF was used for the refinement of peak assignments. All significant signals in the NMR spectra were identified and assigned to metabolites using a spectral database of the Bruker company "AMIX" software, as well as the public database HMDB (Human Metabolome Database). Relative concentrations (i.e., fractions of total soluble compounds) of metabolites in the rat brain were calculated for the most significant signals in the NMR spectra. For ease of presentation, each metabolite concentration was normalized to the difference between individual minimal and maximal values (% max-min) and plotted as group mean 6 SEM. Spectrum processing and calculation of integrals were carried out by the Bruker company "TOPSPIN" program.
Statistical Analysis and Signal Processing
Group measures were expressed as mean 6 SEM. Statistical significance was assessed using Wilcoxon signed paired and Wilcoxon rank-sum tests. The level of significance was set at P < 0.05. In figures: *P < 0.05, **P < 0.01, ***P < 0.001. Signal analysis was performed using the IgorPro software (WaveMetrics, Inc.) with custom macros.
RESULTS
Changes in Neuronal Parameters Caused by Acute Glycolysis Inhibition
In hippocampal slices, application of 7 mM 2-DG induced a gradual decrease of evoked local field potentials (eLFPs) (Fig. 1Aa ) measured in both CA1 and dentate gyrus layers (by 49% 6 5%, n 5 6, P < 0.01 and 25% 6 6%, n 5 4, P < 0.03, respectively; Fig. 1Ab ).
In one CA1 slice, however, eLFPs did not decrease and instead exhibited multiple secondary population spikes under 2-DG, indicating network hyperactivity (see inset in Fig. 1Aa) . Moreover, repetitive synaptic stimulation (10 Hz, 10 sec) revealed irregular effects of 2-DG on the network response, with total eLFP train integrals varying between 114% and 42% of control (mean value of 76 6 12, n 5 6, P 5 0.099). Meanwhile, in dentate gyrus granule cells, 2-DG induced a significant depolarization of both E m (from 287.6 6 2.3 to 273.3 6 1.5 mV, n 5 8, P < 0.01) and E GABA (from 285.8 6 3.1 to 276.6 6 2 mV, n 5 6, P < 0.05) measured 1 hr after 2-DG application using the gramicidin-perforated patch technique (Fig. 1Ac) . These effects were not 2-DG Fig. 1 . Metabolic and electric parameters under inhibition of glycolysis in hippocampal slices. A: a) In CA1 region, 2-DG (7 mM 1 5 mM glucose, inhibiting glycolysis by about 35%) decreased eLFPs (40 min following 2-DG application) evoked by stimulation of Schaffer collaterals. In one slice, however, eLFPs did not decrease and revealed multiple secondary spikes (see inset) indicating network hyperexcitability; b) 2-DG decreased eLFPs in both CA1 (n 5 6, P < 0.001) and dentate gyrus (n 5 4, P < 0.03) regions; and (c) 2-DG induced depolarization of the resting membrane potential (E m ; n 5 8, P < 0.01) and the reversal potential of GABAmediated currents (E GABA ; n 5 6, P < 0.05), measured in granule cells by the gramicidin perforated patch method. B: 2-DG also reduced NAD(P)H transients (a) in response to synaptic stimulation (10 Hz, 10 sec) in both CA1 (n 5 6, P < 0.001) and dentate gyrus (n 5 4, P < 0.03) (b), with the dip/overshoot ratio significantly increased (c) in line with inhibited glycolysis (Ivanov et al., 2014) . C: 2-DG significantly reduced oxygen consumption during synaptic stimulation. D: a) Inhibition of mitochondrial respiration by 0.1 mM 2,4-dinitrophenol (DNP) induces depolarization of the resting membrane potential (E m ; n 5 9, P < 0.01) and E GABA (n 5 8, P < 0.001), measured in L2/3 pyramidal cells by cell-attached patch recordings of single NMDA and GABA receptor channel; b) similar effects were obtained by lowering the ACSF glucose concentration to 0.2 mM (n 5 6, P < 0.05 and 0.01 for E m and E GABA , respectively). Both conditions reduce intracellular ATP concentration by a similar extent (Okamoto and Quastel, 1970) . specific and could be reproduced by other means of energy metabolism inhibition such as lowering ACSF glucose concentration down to 0.2 mM or application of dinitrophenol (0.1 mM), an inhibitor of oxidative phosphorylation (Fig. 1D, single-channel recordings) .
In both CA1 and dentate gyrus, 2-DG modified NAD(P)H autofluorescence transients in response to repetitive synaptic stimulation (10 Hz, 10 sec, Fig. 1Ba,  b) : the amplitudes of both transient components, "dip" (oxidation) and "overshoot" (reduction), were reduced, while the NAD(P)H dip/overshoot ratio significantly increased (Fig. 1B, c ; n 5 6, P < 0.001 and n 5 4, P < 0.03 for CA1 and DG signals, respectively), confirming inhibited glycolysis (Ivanov et al., 2014) . The stimulation-induced oxygen consumption in CA1 was also significantly decreased by 2-DG (Fig. 1C) . The reduced NAD(P)H fluorescence and oxygen consumption may not be attributed to an inhibited network response to stimulation, as the reduction in both parameters was observed in all experiments, even those where the overall response (train eLFP integral) increased following 2-DG application.
Thus, acute inhibition of glycolysis in slices depolarizes neurons and decreases GABAergic inhibition, increasing postsynaptic excitability, but at the same time it may reduce the efficacy of excitatory synaptic transmission. Presumably, these opposing effects on network excitability could reconcile the pro-and anticonvulsive acute effects of 2-DG reported in vivo (Gasior et al., 2010) .
Chronic Inhibition of Glycolysis Initiates Epileptogenesis in vivo
To investigate the long-term consequences of 2-DG effects in vivo, we recorded brain activity in freely moving rats prior to and following chronic glycolysis inhibition by direct suppression of brain glycolysis via daily intraventricular 2-DG injections (10 rats with 2-DG, 8 rats with vehicle treatments). In 2 rats, we detected intensive spontaneous seizure activity following 4 weeks of the 2-DG treatment (average number 42.3/hr and 26.6/hr with average duration 57.9 sec and 38.6 sec, respectively), while none were detected in other 2-DGtreated or vehicle-treated rats. Representative LFPs recorded in one of these 2 rats before and after 4 weeks' 2-DG treatment are shown in Figure 2A . The insets display short periods of "quiescent" baseline activity where clear theta-rhythm oscillations are present prior to treatment (left), while this activity is completely disrupted following 2-DG treatment (right). Indeed, 2-DG administration resulted in the significant increase of signal power at both low frequencies (together with a switch in dominating frequency) and higher frequencies (Fig. 2Ba) .
The 2-DG-treated rats without spontaneous seizures (n 5 8) also showed abnormal activity of the neuronal network. As seen in Figure 2D , normalized average PSDs (all rats; in each rat, PSD was normalized to the total PSD integral) demonstrate a significant reduction of power at delta-range frequencies (1-4 Hz) in 2-DG-treated rats. In addition, these animals exhibited a hyperactive network state seen as a significant increase in "suprabasal" activity evaluated as signals with amplitude exceeding the basal level. Such events may be triggered by different types of physiological or pathological activity, and their accumulated levels may serve as a measure of the network's excitability. We calculated this accumulated activity (see Methods) for consecutive 20-sec periods in all LFP recordings, averaged them across each rat group (Fig. 2E) , and found a strong increase in the LFP accumulated activity following 2-DG treatment, indicating a high level of induced paroxysmal activity. The treatment also resulted in a significant increase in the number of high-amplitude spikes (from 10.9 6 4.0 to 29.2 6 12.8 per 10 min of recordings, n 5 10; P < 0.02; Fig. 2F ; also see Methods). Moreover, 2-DG induced the generation of multiple HFBs detected in the frequency range of 60 to 250 Hz (from 4.2 6 1.9 to 32 6 14.5 per 10 min of recordings, n 5 10; P < 0.01; Fig. 2G ; see "LFP analysis" in Methods). HFBs have been reported in EEGs of epileptic patients and in animal epilepsy models and are thought to reflect pathological activity corresponding to epileptogenesis (Bragin et al., 1999; Jirsch et al., 2006; Levesque et al., 2011) . The PTZ seizure test (evaluates a change in excitability of nervous tissue; see Methods) revealed a decreased seizure threshold in 2-DG-treated rats (Fig.  2C ). In total, three 2-DG-treated rats have died, one because of a strong tonic-clonic seizure during a recording session (Fig. 2Bb) and two others at night (presumably due to seizures as well). These events, together with recorded parameters and analysis, provide strong evidence that 2-DG does indeed induce network hyperexcitability leading to spontaneous seizures.
Altogether, these results clearly show that chronic inhibition of glycolysis leads to the abnormal state of neural network resembling epileptogenesis. Fig. 2 . Chronic inhibition of brain glycolysis triggers epileptogenesis in rats. In freely moving rats, daily i.c.v. injections of 2-DG resulted in the development of paroxysmal activity. A: Representative LFP recordings in one rat before (blue traces) and after 2-DG treatment (red traces); the insets (arrows) clearly indicate a difference in oscillatory activity during quiescent periods. B: a) Power spectral densities (PSDs) of LFP recordings shown in A, and b) example of a tonicclonic seizure that led to the death of a rat during a recording session. C: Average seizure severity before (blue, black traces) and after (red, gray traces) 2-DG/vehicle treatment measured following 35 mg/kg PTZ injection. D: Average power spectral densities (all normalized to the total PSD integral) in different rat groups measured before and after treatment (10 rats in the 2-DG group and 5 rats in the vehicle group). At the delta frequency range (1-4 Hz), the PSD peak is significantly smaller under the action of 2-DG. E: The 2-DG treatment strongly increased accumulated activity averaged for all rats in each group. F: The 2-DG treatment increased the number of LFP high-amplitude spikes (sharp waves, measured in the 50-to 990-msec time range) and (G) high-frequency bursts (HFBs; measured in the 100-to 250-Hz range; see Methods for details).
Pathological Changes Obtained in Brain Slices from 2-DG-treated Rats
Ex vivo measurements in the hippocampal slices from chronically 2-DG-treated animals revealed that their neurons are much less tolerant of glucose deprivation (low-glucose solution, 0.1 mM) compared with the vehicle-treated animal slices (Fig. 3A) . The time to 50% decay of eLFP integrals in the 2-DG group was half that Fig. 3 . Metabolic and electric parameter changes in ex vivo hippocampal slices and tissue samples from 2-DG-treated rats. A: Ex vivo measurements in the hippocampal slices from chronically 2-DGtreated animals revealed that their neurons are much less tolerant of glucose deprivation compared with the vehicle-treated animal slices.
B:
In slices from 2-DG-treated rats (channel recordings in dentate gyrus), E m did not change (n 5 29, P > 0.2), while E GABA depolarized significantly (P < 0.01, n 5 20). C: Results of NMR analysis of brain tissue samples (control [vehicle] rats, n 5 5; 2-DG rats, n 5 5). N-AcAsp indicates N-acetyl-aspartate.
of vehicle-treated rats (approximately 25 min, n 5 11, vs. > 70 min, n 5 12; P < 0.001), likely because of reduced glycogen stores (Fig. 3C) . Similar protocols have been used previously to ascertain the glycogen stores and their support of neuronal activity (Brown and Ransom, 2007; Zilberter et al., 2013) .
Measurements in individual neurons (dentate gyrus granule cells) in ex vivo slices also showed that although E m did not change (279.3 6 2.3 and 282 6 2.4 mV, n 5 29, P > 0.2), E GABA was significantly depolarized in neurons from 2-DG-treated rats (267.2 6 4.0 vs. 283.7 6 3.4 mV, n 5 29, P < 0.01; Fig. 3B ), suggesting a strong decrease in efficacy of the inhibitory drive. This may be one cellular mechanism underlying the development of network hyperexcitability during the 2-DG treatment.
NMR analysis of brain samples of 2-DG-treated rats revealed significant detrimental changes in their brain energy reserves (decreased glycogen and adenosine phosphates, increased adenosine), and mitochondrial metabolism (decreased succinate) (Fig. 3C ).
DISCUSSION
Our results suggest that chronic hypometabolism, characteristic of the well-established risk factors of acquired epilepsy such as traumatic brain injury, stroke, viral infection, status epilepticus (Pitkanen et al., 2015; Waldbaum and Patel, 2010) , and, specifically, reduced glucose utilization (typically observed in epileptic patients), can readily initiate epileptogenesis. In turn, we found recently (P.I., personal communication) that seizures themselves result in a fast and long-lasting downregulation of glucose utilization, thus completing the vicious cycle of epilepsy initiation and progression. We have proposed that it is the deficiency in energy supply (Kudin et al., 2009; Jupp et al., 2012; Lee et al., 2012; Reid et al., 2014) , associated with oxidative stress (Azam et al., 2012; Martinc et al., 2012) and neuroinflammation (Wilcox and Vezzani, 2014) , that is a trigger and driving force for acquired epileptogenesis. The results of the present study provide a missing link between deficient brain energy metabolism associated with the risk factors and the initiation of epileptogenesis.
Regarding epilepsy treatment, our results demonstrate that chronic inhibition of brain energy metabolism is a dangerous strategy, as it would further aggravate the metabolic crisis already established during epileptogenesis (Kudin et al., 2009; Jupp et al., 2012; Lee et al., 2012; Reid et al., 2014) . It is unlikely that such suppression of energy supply contributes to the observed antiepileptic action of KD as has been suggested, since ATP synthesis was reported to be normal or increased during KD (Maalouf et al., 2009) , while ATP levels in brain tissue either remained unchanged (Bough et al., 2006; Nylen et al., 2009 ) or increased (DeVivo et al., 1978 Nakazawa et al., 1983) . The high oxidative capacity for glucose during KD irrespective of ketotic or nonketotic state was reported (Zhang et al., 2013a) , although reduced cerebral glucose metabolic rates were also found (Zhang et al., 2013b; but see al-Mudallal et al., 1995) . We conclude that some reduction in glycolysis is possible during KD due to a partial substitution of glucose by ketone bodies for mitochondrial fueling; however, this should not be considered an overall inhibition of energy metabolism.
Previous studies have attempted to replicate the antiepileptic effects of KD through glycolysis inhibition by intravenous injection of 2-DG immediately prior to kindling procedures (Garriga-Canut et al., 2006; Stafstrom et al., 2009) . The authors show a significant abatement of both the kindling efficiency and the resulting epilepsy across different kindling methods and 2-DG doses (75-500 mg/kg) and suggest that the 2-DG effects are underlain by direct brain glycolysis inhibition. However, this conclusion is difficult to support when one estimates the resulting blood and brain 2-DG concentrations, something that was not done in those studies. One study in rats showing ischemia-induced mortality prevention by 2-DG used 1.6 g/kg i.p. injection and reported resulting blood 2-DG levels of up to 1.6 mM (Combs et al., 1986) . Assuming similar transport across the blood-brain barrier for 2-DG and glucose and the typical 5:1 glucose gradient (6 mM blood vs. 1.3 mM brain ECF [Zilberter et al., 2010] ), this would translate into 0.32 mM brain 2-DG concentration. This calculation may somewhat underestimate the 2-DG level since the low ECF glucose is likely maintained by efficient cell consumption. However, and intriguingly, 2-DG injection also results in a concurrent and significant rise of blood glucose levels and cerebral blood flow, as has been reported for both animals (Combs et al., 1986; Breier et al., 1993; Horinaka et al., 1997) and humans (Landau et al., 1958; Elman et al., 1999) . These factors should result in a corresponding increase in brain ECF glucose. Using the same calculations for glycolysis inhibition as used in our Methods and given the resulting brain 2-DG and glucose concentrations, we can estimate that even at the highest 2-DG dose used for antiepileptic treatment (500 mg/kg), brain glycolysis inhibition should only have been at about 1% to 2%, a negligible amount. Thus, it is much more likely that i.p. 2-DG injections exert their antiseizure action through systemic-driven effects, such as the aforementioned transient increase in brain glucose availability as well as cerebral blood flow. In our in vivo experiments, intraventricular 2-DG injections at the concentrations used should have transiently inhibited brain glycolysis by approximately 14% (see Methods). Such magnitudes are unlikely to cause massive morphological disruptions or cell death, leading us to conclude that it is the direct and partial inhibition of brain glycolysis that is responsible for the observed epileptic phenotype. Indeed, single intraventricular 2-DG injections have been used to study the effects of glucoprivation on feeding behavior in rats (Minami et al., 1995; Briski and Sylvester, 2001) , at concentrations exceeding ours by more than 10-fold, suggesting that intraventricular administration is efficient in terms of brain cell survival and glycolysis inhibition. Otherwise, given the chronic nature of 2-DG treatment, as well as the intraventricular administration method, it is therefore quite difficult to directly compare our in vivo results with those of previous studies.
A recent study using LDH blockade as an alternative method of energy metabolism inhibition reported a significant acute anticonvulsant effect. Glycolysis inhibition by intraperitoneal or intrahippocampal injection of LDH blockers was shown to acutely reduce the frequency of high-voltage spikes in hippocampi of kainate-injected mice (Sada et al., 2015) . As a possible mechanism of LDH blockade action, the authors proposed that LDH inhibition leads to a blockade of lactate production and release from astrocytes with a resulting energy shortage in neurons, activating hyperpolarizing currents through K ATP channels and abolishing hyperexcitability of the network.
However, all in vitro recordings in that study were made at room temperature and with ACSF containing 2.5 mM glucose, which the authors justified as an "in vivo-like" concentration. At the same time, the glucose consumption differs drastically between in vitro slices and in vivo. In slices, basal glucose concentration inside the tissue is almost half that of the perfusate solution because of substantial resting-state consumption (see Fig. 4A ). Fig. 4 . Examples of metabolic substrate transients in response to synaptic stimulation in a hippocampal slice and in hippocampus of a freely moving mouse. A: A Clark-style oxygen microelectrode (tip diameter 10 mm; Unisense Ltd.) was used to measure slice tissue pO 2 . Tissue extracellular glucose and lactate concentrations were measured with enzymatic microelectrodes (Sarissa Biomedical, Coventry, UK). All sensors were placed in the stratum radiatum near the site of LFP recording. B: Sensor electrodes (Blue Box Sensors Ltd.) were implanted in the mouse hippocampus. Electrodes were connected to a picoammeter (Unisense Ltd.). Calibration is given as a percentage of baseline level.
During synaptic activation, extracellular glucose and oxygen levels drop and slowly recover following the stimulation. In contrast, in the living brain, glucose and oxygen consumed during network activation are rapidly replenished from blood vessels (see Fig. 4B ). Therefore, at 2.5 mM glucose in ACSF, the glucose concentration in slice tissue is about 1 mM even at rest, which certainly is a glucopenic state, and reduces further during synaptic stimulation.
The interpretation of in vivo results by (Sada et al., 2015) arises from the assumption of a unidirectional lactate flow from astrocytes into neurons and its utilization as the energy fuel. However, our recordings of lactate release both in slices and in vivo show no indication of massive lactate consumption induced by network activation-quite the opposite, we recorded a massive lactate release instead (see Fig. 4 ). Despite the fact that lactate can certainly be used as an energy source, it seems that at normal conditions a fraction of pyruvate in neurons is converted by LDH to lactate and released to the extracellular space. If that is the case, then the blockade of LDH may indeed lead to a significant energy deprivation via pyruvate-induced inhibition of glycolysis. For instance, Sada et al. showed that inhibition of LDH resulted in a 70% reduction in excitatory postsynaptic currents, most likely due to a decrease in synaptic transmitter release (as the postsynaptic target cells were recorded in whole-cell configuration with 4 mM ATP in the intracellular solution, preventing any energy shortage from LDH blockade). Presynaptic machinery presumably relies mostly on glycolysis-provided ATP (Lujan et al., 2016) , and therefore the reported LDH effect was most likely underlain by presynaptic glycolysis inhibition. Thus, similar to the acute effects of 2-DG, the initial decrease in network activity induced by energy deprivation can cause a shortterm antiseizure effect, although an opposite proseizure effect cannot be excluded (see Gasior et al., 2010) . Our results show as well (see Fig. 1A ) that energy deficiency, depending on the balance between evoked downregulation of synaptic transmission and depolarization of E m and E GABA , may cause bidirectional effects.
In conclusion, the results of this study support our conceptual view on acquired epilepsy as a metabolic disease, highlighting the risks of brain energy metabolism inhibition as a treatment strategy.
